There have been arguments about the role of breast cancer screening at the population level, and some points of controversy have arisen, such the establishment of organized screening policies and the age at which to begin screening. The real benefit of screening has been questioned because the results of this practice may increase the diagnosis of indolent lesions without decreasing mortality due to breast cancer. The authors have proposed a study of incidence and mortality trends for breast cancer in a developing setting in Brazil to monitor the effectiveness of the official recommendations that prioritize the age group from 50 to 69 years. The database of the Cancer Registry and the Mortality Information System was used to calculate age-standardized and age-specific rates, which were then used to calculate incidence and mortality trends using the Joinpoint Regression Program. The results showed stability in trends across all ages and age-specific groups in both incidence and mortality. In conclusion, we found that incidence and mortality rates are compatible with those in regions with similar human development indexes, and trends have demonstrated stabilization. Thus, we do not endorse changes in the official recommendations to conduct screening for ages other than 50 to 69 years, nor should policy makers implement organized screening strategies. Considering the epidemiological transition of developing countries, breast cancer has become a growing burden in these areas 1. Brazil has been experiencing increasing incidence rates, especially in state capitals and more developed regions 2. Mortality rates have also remained high 3. Breast cancer is the type of cancer with the highest mortality rate among women. Brazilian cancer registries cover less than 50% of the Brazilian population, and incidence rates are obtained by estimates made by the Brazilian National Cancer Institute (INCA) every two years. It has been estimated that the mean age-standardized incidence rate for 2018-2019 in Brazil is 51.3 per 100,000 women; in the state capitals, the estimated rate is 64.0 per 100,000 women 4. Information regarding the impact of mortality comes from the analysis of the database of the Mortality Information System (SIM). For 2016, the age-standardized mortality rate in Brazil was 12.7 per 100,000 women 5. The role of screening has been discussed, including whether it has actually been effective in decreasing mortality and not just increasing survival and whether the difference is due only to the overdiagnosis of approximately 30% additional cases obtained by screening mammography 6-8. A major point of argument regarding screening has been the age at which to start. Many organizations associated with cancer control have advocated starting screening at the age of 40 years, emphasizing the associated increase in survival. However, we must consider the possibility of diagnosing indolent lesions, which inflates the incidence statistics and leads to consequent overtreatment that could be harmful to the patient 9-11 .